Acute myeloid leukaemia

37 trials 14 recruiting MedDRA PT
37 Registered trials
14 Recruiting
24 Unique sponsors
19 Unique IMPs
23 Commercial trials
Drug classes (ATC)
— ATC code not specified 22
L Oncology (ATC L) 16
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Kinase inhibitor 6 substances
Antimetabolite 4 substances
BCL-2 inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Phase III: 6 Phase II: 16 Phase I/II: 3 Phase I: 5 Phase I (Other): 4 Phase I (First in Human): 4

Filter these 37 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 37 trials

Phase III

6 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    VENETOCLAX
    2023-507222-17-00 7 countries 2020 n=120
    Ended
  • Kura Oncology Inc. Commercial
    DAUNORUBICIN HYDROCHLORIDE; ZIFTOMENIB
    2025-521314-25-00 10 countries 2026 n=719 Orphan
    Recruiting
  • Fondazione Gimema Franco Mandelli Onlus Academic
    CYTARABINE
    2023-505901-17-00 1 country 2020 n=172
    Recruiting
  • Fundacion PETHEMA Academic
    QUIZARTINIB DIHYDROCHLORIDE
    2025-522979-29-00 1 country 2026 n=350
    Recruiting
  • Medical University Of Lodz Academic
    CLADRIBINE; GEMTUZUMAB OZOGAMICIN; VENETOCLAX
    2023-503394-37-00 1 country 2024 n=520
    Recruiting
  • The University Of Birmingham Academic
    GEMTUZUMAB OZOGAMICIN
    2024-516112-21-00 2 countries 2017 n=289 Orphan
    Ended

Phase II

16 trials
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE
    2023-505910-10-00 4 countries 2024 n=174
    Ended
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE
    2023-505911-19-00 4 countries 2024 n=129
    Recruiting
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE; RUXOLITINIB
    2025-521673-14-00 4 countries 2025 n=29
    Recruiting
  • Syros Pharmaceuticals Inc. Commercial
    TAMIBAROTENE
    2024-510939-21-00 1 country 2022 n=60 Orphan
    Ended
  • Syros Pharmaceuticals Inc. Commercial
    TAMIBAROTENE
    2024-516281-11-00 1 country 2018 n=1 Orphan
    Ended
  • Taiho Oncology Inc. Commercial
    DECITABINE, CEDAZURIDINE
    2024-516293-29-01 8 countries 2022 n=100
    Ended
  • Taiho Oncology Inc. Commercial
    DECITABINE, CEDAZURIDINE; VENETOCLAX
    2024-516294-78-00 1 country 2022 n=40
    Ended
  • Fondazione Gimema Franco Mandelli Onlus Academic
    IMP not specified
    2023-510432-36-00 1 country 2022 n=35
    Ended
  • French Innovative Leukemia Organization Academic
    AZACITIDINE; GILTERITINIB
    2022-501372-25-00 1 country 2024 n=33 Orphan
    Ended
  • French Innovative Leukemia Organization Academic
    IMP not specified
    2022-502392-37-00 1 country 2022 n=114
    Ended
  • French Innovative Leukemia Organization Academic
    AZACITIDINE; IVOSIDENIB
    2025-521322-14-00 1 country n=60
    Pending
  • Fundacion PETHEMA Academic
    DECITABINE, CEDAZURIDINE; IVOSIDENIB
    2025-523238-17-00 1 country n=50 Orphan
    Pending
  • Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare Academic
    DECITABINE; VENETOCLAX
    2024-518792-54-00 1 country 2021 n=100
    Ended
  • Hellenic Society Of Hematology Academic
    GILTERITINIB
    2025-521875-30-00 1 country n=58 Orphan
    Pending
  • Rigshospitalet Academic
    DECITABINE, CEDAZURIDINE
    2023-510415-19-00 4 countries 2024 n=147
    Recruiting
  • The University Of Birmingham Academic
    VENETOCLAX
    2024-516116-19-00 1 country 2025 n=10
    Recruiting

Phase I/II

3 trials
  • Cellcentric Limited Commercial
    INOBRODIB
    2024-519498-20-00 1 country 2025 n=16
    Recruiting
  • Incyte Corp. Commercial
    PONATINIB
    2023-509699-41-00 6 countries 2019 n=57 Orphan
    Recruiting
  • Fondazione Gimema Franco Mandelli Onlus Academic
    VENETOCLAX
    2023-510517-26-00 1 country 2018 n=124
    Ended

Phase I

5 trials
  • Auron Therapeutics Inc. Commercial
    IMP not specified
    2025-521394-13-00 1 country n=10
    Pending
  • Byondis B.V. Commercial
    IMP not specified
    2023-507781-13-00 3 countries 2024 n=33
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2022-500573-13-00 1 country 2021 n=22
    Ended
  • LAVA Therapeutics N.V. Commercial
    IMP not specified
    2024-518831-12-00 1 country 2025 n=20
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-506945-42-00 1 country 2022 n=8
    Recruiting

Phase I (Other)

4 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-506117-22-00 5 countries 2022 n=153
    Ended
  • Taiho Oncology Inc. Commercial
    IMP not specified
    2024-516291-16-00 5 countries 2021 n=46
    Recruiting
  • Taiho Oncology Inc. Commercial
    IMP not specified
    2024-516292-33-00 5 countries 2021 n=50
    Ended
  • Celgene Corp. Academic
    IMP not specified
    2023-506117-22-00 5 countries 2022 n=153
    Ended

Phase I (First in Human)

4 trials
  • Aptose Biosciences Inc. Commercial
    IMP not specified
    2023-503244-14-00 4 countries 2023 n=103
    Ended
  • Ellipses Pharma Limited Commercial
    AZACITIDINE; EP0042; VENETOCLAX
    2024-514588-24-00 1 country 2021 n=13
    Halted
  • Miltenyi Biomedicine GmbH Commercial
    IMP not specified
    2023-505806-41-00 1 country 2024 n=32
    Recruiting
  • Molecular Partners AG Commercial
    ANTIBODY MIMETIC PROTEIN BINDING TO T CELLS CD3, TUMOR-ASSOCIATED ANTIGENS CD70, CD33, CD123, AND HUMAN SERUM ALBUMIN; AZACITIDINE; VENETOCLAX
    2023-505259-39-00 3 countries 2023 n=221
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Taiho Oncology Inc. Commercial 4 Phase I (Other), Phase II 1
Celgene Corp. Commercial 3 Phase I, Phase I (Other) 0
Ryvu Therapeutics S.A. Commercial 3 Phase II 2
Fondazione Gimema Franco Mandelli Onlus Academic 3 Phase II, Phase III, Phase I/II 1
French Innovative Leukemia Organization Academic 3 Phase II 0
Syros Pharmaceuticals Inc. Commercial 2 Phase II 0
Fundacion PETHEMA Academic 2 Phase II, Phase III 1
The University Of Birmingham Academic 2 Phase II, Phase III 1
Auron Therapeutics Inc. Commercial 1 Phase I 0
Byondis B.V. Commercial 1 Phase I 0
LAVA Therapeutics N.V. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase III 0
Kura Oncology Inc. Commercial 1 Phase III 1
Aptose Biosciences Inc. Commercial 1 Phase I (First in Human) 0
Ellipses Pharma Limited Commercial 1 Phase I (First in Human) 0
Miltenyi Biomedicine GmbH Commercial 1 Phase I (First in Human) 1
Molecular Partners AG Commercial 1 Phase I (First in Human) 1
Cellcentric Limited Commercial 1 Phase I/II 1
Incyte Corp. Commercial 1 Phase I/II 1
New trials by year
2019
1
2020
2
2021
5
2022
8
2023
2
2024
7
2025
4
2026
2
← All indication landscapes